Repligen Corporation’s $138 Million Follow-on Offering

Covington advised the underwriters in a $138 million follow-on public offering of common stock by Repligen Corporation.

Covington previously represented the underwriters in Repligen’s $115 million convertible note offering in May 2016.

J.P. Morgan and Stephens Inc. acted as Joint Book-Running Managers, Janney Montgomery Scott acted as Lead Co-Manager and Craig-Hallum Capital Group acted as Co-Manager.

Repligen is a bioprocessing company focused on the manufacture of Protein A ligands, cell culture growth factors, and filtration and chromatography products used by life science companies to manufacture and purify biologic drugs such as monoclonal antibodies, recombinant proteins, and vaccines.

The Covington corporate team was led by Don Murray (Picture), Brian Rosenzweig, Matt Gehl, and John Mei.

Involved fees earner: Donald Murray – Covington & Burling; Brian Rosenzweig – Covington & Burling; Matthew Gehl – Covington & Burling; John Mei – Covington & Burling;

Law Firms: Covington & Burling;

Clients: JP Morgan; Stephens Inc.; Janney Montgomery Scott LLC.; Craig-Hallum Capital Group LLC;


Author: Ambrogio Visconti